{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-108192","form_type":"8-K","ticker":"BJDX","cik":"0001704287","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.204499+00:00","generated_at":"2026-05-16T22:28:18.623755+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bluejay Diagnostics Q3 update: SYMON-II 50% enrolled, $3.08M cash, needs $20M more by 2027","bullets":["Q3 cash $3.08M; stockholders' equity $3.69M. Raised $3.85M in April and $4.5M PIPE in October.","SYMON-II pivotal trial patient enrollment ~50% completed; sample testing expected late 2026 subject to financing.","Company expects to need at least $20M additional capital by end of FY2027 to fund operations and FDA submission.","Amended agreements with SanyoSeiko to expand manufacturing role for Symphony platform commercialization.","No revenue reported; pre-commercial stage; Symphony IL-6 test targets sepsis diagnostics, market projected at $1.8B by 2030."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-108192","json":"https://secwatch.observer/filing/0001213900-25-108192.json","markdown":"https://secwatch.observer/filing/0001213900-25-108192.md","text":"https://secwatch.observer/filing/0001213900-25-108192.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000121390025108192/0001213900-25-108192-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000121390025108192/ea0264778-8k_bluejay.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:28:18.623755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}